Icahn Leaves Pool, Genzyme Shareholder No More
This article was originally published in The Pink Sheet Daily
Executive Summary
Cambridge neighbor Biogen Idec, meanwhile, girds for a power struggle at its May annual meeting.
You may also be interested in...
Biogen Idec Clears The Air: No Large Companies Meet Dual Test For Acquisition
Putting a “permanent for sale sign out on the front lawn” is not the appropriate way to run the biotech either, CEO Mullen maintains.
Biogen Power Struggle: Icahn Seeks Board Seats
Billionaire investor Icahn asserts Biogen intentionally derailed a search for a buyer by refusing to allow interested parties to speak with its Tysabri partner, Elan.
Genzyme Sales Of Myozyme Doubled In Fourth Quarter 2007
Enzyme replacement therapy for Pompe disease recorded $62 million in sales in the quarter, representing the most rapid growth of any of the firm’s lysosomal products.